⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MAZE News
Maze Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
MAZE
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
globenewswire.com
MAZE
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
globenewswire.com
MAZE
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
prnewswire.com
MLYS
PROK
IRON
REGN
AMGN
MAZE
LLY
JNJ
LXRX
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
globenewswire.com
MAZE
Zifo and Maze Therapeutics Partner to Power Precision Medicine
prnewswire.com
MAZE
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
MAZE
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
MAZE
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
globenewswire.com
MAZE
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
globenewswire.com
MAZE